Colorectal Cancer Clinical Trials

Showing 401-420 of 1,434 trials

Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

NCT05534087

This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to standard treatment (FOLFOX/CAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX/CAPOX chemotherapy

Colon Cancer

Seoul National University Hospital236 participantsStarted Dec 2022

Goyang, South Korea • Seongnam, South Korea • Seoul, South Korea

COMPLETED

Predictors of One-Year Mortality After Curative Surgery in Patients Aged 80 Years or Older With Non-Metastatic Colorectal Cancer

NCT06704646

The aim of this study is to determine which preoperative factors are associated with one-year postoperative mortality in patients aged ≥80 years undergoing curative surgery and compare outcomes between patients with or without risk factors.

Colorectal Cancer

National Taiwan University Hospital310 participantsStarted Jan 2014

TERMINATEDPHASE1

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

NCT05824559

This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

Colorectal Cancer

MEI Pharma, Inc.23 participantsStarted Aug 2023

Los Angeles, California, United States • Miami Beach, Florida, United States • Baltimore, Maryland, United States +4 more locations

Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Predictors of One-Year Mortality After Curative Surgery in Patients Aged 80 Years or Older With Non-Metastatic Colorectal Cancer

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Related Searches

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery

Apatinib for Resectable Colorectal Cancer

Effect of Patient Navigation on Colonoscopy Completion Screening Rate for Colorectal Cancer.

Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

Pilot Study of a National Screening Programme for Bowel Cancer in Norway

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.

Test Up Now Education Program

HIPEC for Peritoneal Carcinomatosis

TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer